VolitionRx (NYSE-A:VNRX) Limited has announced the appointment of Sharon Ballesteros as the company’s new US head of quality and development process.
VolitionRx (NYSE-A:VNRX) said Ballesteros has more than 20 years of experience within the in-vitro diagnostics industry with senior program management, quality assurance, and process improvement roles at companies such as Siemens Health Diagnostics, Thermo Fisher, and Agena Bioscience.
“Her leadership skills, industry knowledge and expertise in quality assurance, regulatory affairs and process improvement will be invaluable to us, as we develop and implement a robust clinical study and FDA regulatory program, and help bring our range of Nu.Q products to market,” VolitionRx (NYSE-A:VNRX) chief operating officer Gaetan Michel said in a statement.
READ: VolitionRx makes ‘good progress’ in key areas as it ends 2021 with over $20M in cash
The company noted that Ballesteros joins Volition's wholly-owned Volition America subsidiary as it expands its team and operations in California and opens a new 6,000 square foot, state-of-the-art innovation laboratory in Carlsbad focused on cutting-edge, discovery research.
VolitionRx is a multi-national epigenetics company that has developed simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
The company is mainly focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Contact Sean at sean@proactiveinvestors.com